“…The first study on targeted therapy was conducted when an antibody targeting leukemia cells 77 was linked to methotrexate, also known as amethopterin, which had been proposed as a useful chemotherapy agent. 78,79 In particular, DHFR, an enzyme which is responsible for the conversion of folic acid into tetrahydrofolic acid, is inhibited by methotrexate, although folic acid is required for the biosynthesis of purines and pyrimidines. The activation of DHFR thus inhibits the synthesis of DNA, RNA, thymidylates and proteins 80 resulting in the termination of cell division.…”